Interestingly, dual inhibition of MEK and mTOR dramatically represses hepatocarcinogenesis and lung metastasis and decreases the level of PRELID2, which may provide a potential strategy to treat this aggressive subtype of HCC with elevated FBXL6 and activated KRAS. The gene discussed is MTOR; the disease is hepatocellular carcinoma.